Drugs / AS-S603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06786676 | May 2025 → Dec 2026 expected | — | Amyloid Solution Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-11 | Amyloid Solution Inc | Regulatory Phase 1 IND approval in Korea for our innovative Alzheimer's therapeutic, AS-S603 amyloidsolution.com ↗
We are thrilled to announce that Amyloid Solution has received Phase 1 IND approval in Korea for our innovative Alzheimer's therapeutic, AS-S603! |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Amyloid Solution Inc | Amyloid Solution presented AS-S603 and AS-YFluor at AAIC 2025 amyloidsolution.com ↗ |
| 2024-12-11 | Amyloid Solution Inc | Phase 1 IND approval in Korea for our innovative Alzheimer's therapeutic, AS-S603 amyloidsolution.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AS-S603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06786676 ↗ |
| Modality | Small molecule | “It is a small molecule compound that targets and dissolves amyloid-beta (Aβ) and tau aggregates” NCT06786676 ↗ |
| Route | Oral | “orally administered” NCT06786676 ↗ |